A. Rost

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Medicine, Oncology, Pharmacology +9

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann, D. Quietzsch, Frank Gieseler et al. · Journal of Clinical Oncology · 2006 · 684 citations

Medicine, Oncology, Pharmacology +13

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology · 2005 · 440 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer

Salah‐Eddin Al‐Batran, Akin Atmaca, Susanna Hegewisch‐Becker et al. · Journal of Clinical Oncology · 2004 · 184 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma

Eckhart Weidmann, S.-Z. Kim, A. Rost et al. · Annals of Oncology · 2002 · 95 citations · Full text

Medicine, Oncology, Pharmacology +5